KEYTRUDA (pembrolizumab) is first medicine to be made available to patients through U.K. Early Access to Medicines Scheme (EAMS) for advanced melanoma

Merck, known as MSD outside the United States and Canada, has announced that the company's anti-PD-1 therapy, pembrolizumab, which is marketed in the U.S.